Dr. Reddy’s Laboratories (RDY) Projected to Post Earnings on Tuesday

Dr. Reddy’s Laboratories (NYSE:RDY) is projected to release its Q4 24/25 earnings data before the market opens on Tuesday, May 6th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.20 per share and revenue of $83.70 billion for the quarter.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Trading Up 1.2 %

Shares of NYSE:RDY opened at $14.00 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $11.69 billion, a PE ratio of 22.29 and a beta of 0.51. Dr. Reddy’s Laboratories has a 1 year low of $12.26 and a 1 year high of $16.89. The firm has a fifty day moving average price of $13.23 and a 200 day moving average price of $14.15.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.